225 related articles for article (PubMed ID: 34753903)
1. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.
Wang M; Jia J; Cui Y; Peng Y; Jiang Y
Cell Death Dis; 2021 Nov; 12(11):1065. PubMed ID: 34753903
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
3. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
5. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.
Schneider E; Winzer R; Rissiek A; Ricklefs I; Meyer-Schwesinger C; Ricklefs FL; Bauche A; Behrends J; Reimer R; Brenna S; Wasielewski H; Lauten M; Rissiek B; Puig B; Cortesi F; Magnus T; Fliegert R; Müller CE; Gagliani N; Tolosa E
Nat Commun; 2021 Oct; 12(1):5911. PubMed ID: 34625545
[TBL] [Abstract][Full Text] [Related]
6. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.
Arab S; Hasannejad F
Clin Transl Oncol; 2022 May; 24(5):742-756. PubMed ID: 34792724
[TBL] [Abstract][Full Text] [Related]
7. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
[TBL] [Abstract][Full Text] [Related]
8. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A
Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS
J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752
[TBL] [Abstract][Full Text] [Related]
9. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Azambuja JH; Gelsleichter NE; Beckenkamp LR; Iser IC; Fernandes MC; Figueiró F; Battastini AMO; Scholl JN; de Oliveira FH; Spanevello RM; Sévigny J; Wink MR; Stefani MA; Teixeira HF; Braganhol E
Mol Neurobiol; 2019 May; 56(5):3260-3279. PubMed ID: 30117104
[TBL] [Abstract][Full Text] [Related]
10. Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth.
Lopes DV; de Fraga Dias A; Silva LFL; Scholl JN; Sévigny J; Battastini AMO; Figueiró F
Purinergic Signal; 2021 Jun; 17(2):273-284. PubMed ID: 33745072
[TBL] [Abstract][Full Text] [Related]
11. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury.
Zhai X; Chen K; Yang H; Li B; Zhou T; Wang H; Zhou H; Chen S; Zhou X; Wei X; Bai Y; Li M
J Nanobiotechnology; 2021 Sep; 19(1):274. PubMed ID: 34496892
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of CD73 in Cancer.
Bach N; Winzer R; Tolosa E; Fiedler W; Brauneck F
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511518
[TBL] [Abstract][Full Text] [Related]
14. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells.
Quezada C; Garrido W; Oyarzún C; Fernández K; Segura R; Melo R; Casanello P; Sobrevia L; San Martín R
J Cell Physiol; 2013 Mar; 228(3):602-8. PubMed ID: 22833450
[TBL] [Abstract][Full Text] [Related]
15. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function.
Smyth LA; Ratnasothy K; Tsang JY; Boardman D; Warley A; Lechler R; Lombardi G
Eur J Immunol; 2013 Sep; 43(9):2430-40. PubMed ID: 23749427
[TBL] [Abstract][Full Text] [Related]
16. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
17. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
18. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
19. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB; Phan LH; Villarreal OE; Bowser JL
Front Immunol; 2020; 11():508. PubMed ID: 32351498
[TBL] [Abstract][Full Text] [Related]
20. CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment.
Lu T; Zhang Z; Zhang J; Pan X; Zhu X; Wang X; Li Z; Ruan M; Li H; Chen W; Yan M
J Extracell Vesicles; 2022 May; 11(5):e12218. PubMed ID: 35524455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
